This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Results of the citalopram to enhance cognition in Huntington disease trial


Beglinger, Leigh J., Adams, William H., Langbehn, Douglas, Fiedorowicz, Jess G., Jorge, Ricardo, Biglan, Kevin, Caviness, John, Olson, Blair, Robinson, Robert G., Kieburtz, Karl, Paulsen, Jane S.


Movement Disorders: Official Journal Of The Movement Disorder Society, Volume: 29, No.: 3, Pages.: 401-405

Year of Publication



Background: The objective of this study was to evaluate citalopram for executive functioning in Huntington’s disease (HD).; Methods: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and placebo run-ins. The primary outcome was change in executive functioning.; Results: The intent to treat analysis was controlled for practice effects, comparing visits 1 and 2 to visits 5 and 6 for citalopram versus placebo. There were no significant benefits on the executive function composite (treatment-placebo mean difference -0.167; 95% confidence interval [CI], -0.361 to 0.028; P = .092). Citalopram participants showed improved clinician-rated depression symptoms on the HAM-D (t = -2.02; P = 0.05). There were no group differences on motor ratings, self-reported executive functions, psychiatric symptoms, or functional status.; Conclusions: There was no evidence that short-term treatment with citalopram improved executive functions in HD. Despite excluding patients with active depression, participants on citalopram showed improved mood, raising the possibility of efficacy for subsyndromal depression in HD.; © 2013 International Parkinson and Movement Disorder Society.

Bibtex Citation

@article{Beglinger_2013, doi = {10.1002/mds.25750}, url = {}, year = 2013, month = {dec}, publisher = {Wiley-Blackwell}, volume = {29}, number = {3}, pages = {401--405}, author = {Leigh J. Beglinger and William H. Adams and Douglas Langbehn and Jess G. Fiedorowicz and Ricardo Jorge and Kevin Biglan and John Caviness and Blair Olson and Robert G. Robinson and Karl Kieburtz and Jane S. Paulsen}, title = {Results of the citalopram to enhance cognition in Huntington disease trial}, journal = {Movement Disorders} }


adult, aged, citalopram, clinical trial, cognition, cognitive disorders, complications, dementia, depressive disorder, double-blind method, drug administration schedule, drug effects, drug therapy, etiology, executive function, female, humans, huntington disease, male, middle aged, neuropsychological assessment, psychology, therapeutic use, treatment outcome, young adult

Countries of Study


Types of Dementia


Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Antipsychotics and antidepressants